header logo image


Page 9«..891011..2030..»

Archive for May, 2020

OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO and Its Electroporation Gene Delivery System – BioSpace

Wednesday, May 27th, 2020

PENNINGTON, N.J. and SAN DIEGO, May 27, 2020 /PRNewswire/ --OncoSec Medical Inc.(NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent applications covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO and next-generation product candidate TAVOPLUS, and electroporation gene delivery system.

"OncoSec continues to prioritize the expansion of its intellectual property portfolio across multiple facets of its technology," said Keir Loiacono, Vice President, Corporate Development at OncoSec Medical Incorporated. "These three new allowances demonstrate OncoSec's strong patent position in three critical areas: device development, new treatment alternatives and novel adjuvant therapies with previously undescribed combinations. As we look to the future, we believe this will not only help to secure our competitive position in the intratumoral oncology space, but potentially create new opportunities for licensing revenue."

About OncoSec Medical IncorporatedOncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.OncoSec's lead immunotherapy investigational product candidate TAVO (tavokinogenetelseplasmid) enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visitwww.oncosec.com.

TAVO is a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking StatementsThis release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's websitewww.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Company Contact:Gem HopkinsHead of Corporate Communications858-210-7334ghopkins@Oncosec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-strengthens-ip-portfolio-with-three-new-patents-covering-tavo-and-its-electroporation-gene-delivery-system-301066037.html

SOURCE OncoSec Medical Incorporated

Read more from the original source:
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO and Its Electroporation Gene Delivery System - BioSpace

Read More...

ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes – PRNewswire

Wednesday, May 27th, 2020

SAN DIEGO, May 26, 2020 /PRNewswire/ --ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.

Coinciding with the financing, the Company also appointed Ian F. Smithas Executive Chairperson. Mr. Smith was appointed to the Company's Board of Directors in July 2019 and succeeds Fred Middleton, who remains on the board.

Commenting on the financing, Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte, said, "During these difficult times we are grateful for the continued support of our investors as well as our clinical trial participants, whose safety and health remains our focus and commitment. We are steadfast in our mission to deliver potentially life sustaining therapies for patients with insulin-requiring diabetes and to continue the significant progress we have made in the past year. ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Moving forward, we are optimizing the effectiveness of both PEC-Direct and PEC-Encap, the latter of which incorporates novel device material technology created in collaboration with W.L. Gore & Associates. We are also making important progress on our PEC-QT program with our partner, CRISPR Therapeutics, and are now moving into pre-IND activities. This program is designed to eliminate the need for immuno-suppression and could have a transformative impact on a broader population of insulin-dependent patients."

Dr. Laikind continued, "In conjunction with the closure of the financing, we are also pleased to announce the appointment of Ian F. Smith as our Executive Chairperson, succeeding Fred Middleton. Since joining the board last July, Ian and I have worked closely to accelerate ViaCyte's growth and prepare for the future. We are extremely grateful to Fred for his many years of service as Chairperson of ViaCyte's Board of Directors. Throughout his time leading the Board, Fred provided expert guidance as ViaCyte has consistently broken new ground in the field of regenerative medicine and cell replacement therapies."

Mr. Middleton said, "I am proud to have chaired the Board as ViaCyte developed into a leading company in the regenerative medicine field.I am confident that Ian's unique expertise and executive leadership, specifically with innovative growth-oriented companies, and specifically in corporate strategy and operations, as well as capital markets will help ViaCyte progress its important work and firmly establish itself as a leader in the cell therapy sector."

About ViaCyte's Pipeline

The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. Over a decade ago, ViaCyte scientists were the first to report on the production of pancreatic cells from a stem cell starting point and the first to demonstrate in an animal model of diabetes that, once implanted and matured, these cells secrete insulin and other pancreatic hormones in response to blood glucose levels and can be curative. More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. The Company also has a robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide. ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

SOURCE ViaCyte, Inc.

Home

Read more from the original source:
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - PRNewswire

Read More...

UH studying use of convalescent plasma to improve health of COVID-19 patients – Crain’s Cleveland Business

Wednesday, May 27th, 2020

University Hospitals is participating in a study to determine if plasma donated from someone who's recovered from COVID-19 can improve the health of patients battling the virus.

Because patients who've recovered from COVID-19 have antibodies in their blood that could help fight the virus, it is thought that those suffering complications from COVID-19 might improve faster if they receive plasma from the people who've recovered, according to a news release.

Headed at the Christ Hospital in Cincinnati, the study currently has three participating sites in Ohio. Being a part of the study enhances UH's ability to quickly get plasma for patients who need it, according to the release.

"UH is at the forefront of experimental treatments including remdesivir, stem cell therapy and now convalescent plasma," cardiologist Dr. Steven Filby said in a prepared statement. "Patients suffering from extreme complications of COVID-19 have hope at UH thanks to these options."

Filby is a co-investigator for the study, along with Dr. Eiran Gorodeski, an internist and cardiologist at UH Cleveland Medical Center, and Dr. Katharine Downes, a pathologist.

Symptoms of COVID-19 include fever, fatigue, dry cough, headache and more. In addition to respiratory distress, COVID-19 can affect the cardiovascular system. No FDA-approved medicine currently exists to treat or prevent COVID-19, according to the release.

To receive plasmas as part of this study, patients must be hospitalized with COVID-19 and be experiencing "serious complications," including myocardial injury, according to the release.

Blood donations will be collected from patients who are determined recovered and cleared from COVID-19 and who are found to have developed antibodies in their plasma. UH is partnering with Hoxworth Blood Center and Vitalant to provide donations for the study.

"Offering experimental COVID-19 convalescent plasma transfusion to our patients gives us another option to fight COVID-19," Downes said in a prepared statement. "UH appreciates our partnership with the blood suppliers that are crucial to making this happen."

See the article here:
UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business

Read More...

Autologous Stem Cell and Non Stem Based therapies Market 2020 Global Industry Analysis, Trends, Growth Driver, Regional Study and Forecasts to 2025 -…

Wednesday, May 27th, 2020

A research report on Autologous Stem Cell and Non Stem Based therapies Market features a succinct analysis on the latest market trends. The report also includes detailed abstracts about statistics, revenue forecasts and market valuation, which additionally highlights its status in the competitive landscape and growth trends accepted by major industry players.

Autologous Stem Cell and Non Stem Based therapies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in the prevalence of Cancer and Diabetes in all age groups population. Furthermore, the growing geriatric population is another key factor which drives the Autologous Stem Cell and Non Stem Based therapies Market.

Request for Methodology Report @https://brandessenceresearch.com/requestMethodology/PostId/61

Key Players

Autologous Stem Cell and Non Stem Based therapies Marketreports cover prominent players likeBioheart, Antrie Inc., Virxsys, Brainstorm Cell Therapeutics, TiGenix, Cytori Therapeutics Inc.,Tengion Inc.,Dendreon Corporation, Regeneus, Fibrocell, Genesis Biopharma, Orgenesis, Opexa Therapeutics,Neostem, U.S. Stem Cell Inc.,Vericel Corporation, Sanofi, IovanceBiotherapeutics Inc., Mesoblast Ltd., pluristem, Med Cell Europe AG, Anova IRM Stem Cell Center, Stemedica Cell Technologies Inc.,General Electric Company, BioRestorative Therapies,StemGenexamong,Aastrom Biosciences,NeoStem, Inc.,Virxsys, Genzyme Corporation and Georgia Health Science University.

Scope Of Market Reports

Autologous Stem Cell transplantation is a process in which cells from which all blood cells develop are removed, preserved and later given to the same person after severe treatment. In autologous stem cell transplantation, the patient itself acts as stem cell donor. These cells are collected in advance while they are in remission and returned to the patient at a later stage i.e., after two months. They are used to replace stem cells which have been impaired by high doses of chemotherapy.It is important to realize that the processes required in a stem cell transplant are lengthy and complicated. A transplant involves a lot of preparation and a lot of care after procedure. Many people have a single autologous stem cell transplant while others mainly having myeloma or tumors; have two or more continuous transplants.

The initial step in an autologous stem cell transplant is gathering the stem cells. Physicians usually collect stem cells from the bloodstream (peripheral blood stem cells) in advance. A mobilization treatment is used. When the stem cells are in the bloodstream, then collection process starts.The blood is separated using an Apheresis machine. This procedure requires a few hours, and is repeated until the appropriate amount of stem cells is collected. Once the stem cells are harvested, they are frozen in our Stem Cell Processing and Cryopreservation Laboratory until its time to transplant.

Autologous Stem Cell and Non Stem Based therapies Market is segmented on the basis of Application, product, End user and Geography. Based upon ApplicationAutologous Stem Cell and Non Stem Based therapies Market is classified as Neurodegenerative Disorders,Autoimmune Diseases, cancer &Tumors, Cardiovascular Diseases and Others. Based on the ProductAutologous Stem Cell and Non Stem Based therapies Market is classified into Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices and Intracranial Pressure Monitoring Devices. On the basis of End users Autologous Stem Cell and Non Stem Based therapies Market is classified into Hospitals, Ambulatory Surgical Centers and Others.

Market Segmentation

By Application Analysis

By Product Analysis

By End User Analysis

The regions covered in Autologous Stem Cell and Non Stem Based therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Market Dynamics

Rising prevalence of cancer and diabetes among people across all age groups, growing geriatric population, increasing demand for autologous stem cell and non-stem cell based therapies is another factor, which is likely to create a heightened demand. Moreover, Favorable reimbursement policies across several nations are also boosting market. Risks and complications associated with the Autologous Stem Cell and Non Stem Based therapy such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility and thehigh cost of autologous cellular therapies ranging from $500,000 to $1,000,000 restraint the market. Innovation of some newtherapies with improved efficacy, fewer side effects are expected to offer good opportunity for growth of Autologous Stem Cell and Non Stem Based therapies Market in the future.

Regional Analysis

North America is probable to attain the largest share of the Autologous Stem Cell and Non Stem Based therapies Market in terms of revenue and expected to hold the position followed by Europe region. This is due to less risk related with the treatment. Also, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not require an outside donor hence the treatment is less infectious and cheap. However, Asia Pacific is expected to show the high growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Rising healthcare facilities as well as increasing tax and reimbursement procedures is also estimated to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Market Reports

Get Full Report: https://brandessenceresearch.com/chemical-materials/autologous-stem-cell-therapies-market

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact usat: +44-2038074155 ormail usat[emailprotected]

https://www.marketwatch.com/press-release/us-e-learning-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue-emerging-trends-and-business-strategy-till-2025-2020-05-25

https://www.marketwatch.com/press-release/europe-gan-semiconductor-devices-market-covid-19-pandemic-2020-industry-analysis-size-growth-share-trends-segmentation-and-forecast-to-2025-2020-05-25

See the original post:
Autologous Stem Cell and Non Stem Based therapies Market 2020 Global Industry Analysis, Trends, Growth Driver, Regional Study and Forecasts to 2025 -...

Read More...

Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 – Cole of Duty

Wednesday, May 27th, 2020

In the current situation of restricted movement and reduced workforce, (due to COVID-19 Pandemic) new technologies have been developed to provide end-to-end automation in different sectors such as food processing. Automated systems are hired by the companies to ensure continued supply and manufacturing of products with the least manual interference

The advent of Health Information Technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

To Understand How Our Report Information Can Bring Difference, Ask for a brochure @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

Looking for Exclusive Market Insights from Business Experts? Request a Custom Report here @https://www.persistencemarketresearch.com/request-customization/11341

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Our unmatched research methodologies set us apart from our competitors. Heres why:PMRs set of research methodologies adhere to the latest industry standards and are based on sound surveys.We are committed to preserving the objectivity of our research.Our analysts customize the research methodology according to the market in question in order to take into account the unique dynamics that shape the industry.Our proprietary research methodologies are designed to accurately predict the trajectory of a particular market based on past and present data.PMRs typical operational model comprises elements such as distribution model, forecast of market trends, contracting and expanding technology applications, pricing and transaction model, market segmentation, and vendor business and revenue model.

See the article here:
Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 - Cole of Duty

Read More...

Most Definitive & Accurate Study on Frontier Pharma: Breast Cancer First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline…

Wednesday, May 27th, 2020

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

Get Free Sample PDF (Including Full TOC, Tables And Figures) of Market @https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

Unmet need is extremely high in late-stage breast cancer. What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer? What is the current treatment algorithm? How effective are current therapies for these indications, and how does this impact prognosis? The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation. Which molecule types and molecular targets are most prominent across the breast cancer pipeline? What are the relationships between established and up-coming molecular targets in breast cancer? Which first-in-class targets are most promising? How does first-in-class target diversity differ by stage of development and molecular target class? The deals landscape is active and dominated by very high and very low deal values. Which indications attract the highest deal values? How has deal activity fluctuated over the past decade? Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Enquiry For Discount or to Get Customized Report @https://www.researchmoz.us/enquiry.php?type=D&repid=1877885

Reasons to buy

Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options. Identify leading products and key unmet needs within the market. Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target. Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 42 Executive Summary 62.1 Exceptionally Large and Innovative Pipeline 62.2 Alignment of First-in-Class Molecular Target with Disease Causation 62.3 Highly Active Deals Landscape with Numerous Investment Opportunities 63 The Case for Innovation 73.1 Growing Opportunities for Biologic Products 73.2 Diversification of Molecular Targets 83.3 Innovative First-in-Class Product Developments Remain Attractive 83.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 93.5 Sustained Innovation in Breast Cancer 93.6 Report Guidance 94 Clinical and Commercial Landscape 114.1 Overview of Breast Cancer 114.2 Symptoms 114.3 Diagnosis 114.4 Etiology 124.4.1 Age and Gender 124.4.2 Genetics 124.4.3 Environmental 134.5 Pathophysiology 134.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 134.5.2 Tumor Metabolic Shift 144.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 154.5.4 Cancer Stem Cells 164.6 Epidemiology 164.7 Complications 174.8 Prognosis and Disease Staging 184.8.1 Classification 194.9 Introduction to Breast Cancer Treatments 204.9.1 Treatment Algorithm 204.9.2 Treatment Options for Breast Cancer 224.10 Overview of Marketed Products in Breast Cancer 264.11 Current Unmet Needs in the Breast Cancer Market 275 Assessment of Pipeline Product Innovation 295.1 Overview 295.2 Breast Cancer Pipeline by Phase of Development and Molecule Type 295.3 Pipeline by Molecular Target 305.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 325.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 325.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 355.6 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 365.7 List of All First-in-Class Pipeline Programs 38

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on :http://marketresearchlatestreports.blogspot.com/

See the rest here:
Most Definitive & Accurate Study on Frontier Pharma: Breast Cancer First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline...

Read More...

Potential cross-reactivity between MMR vaccinations and COVID-19 | TheHill – The Hill

Wednesday, May 27th, 2020

With the current COVID-19 pandemic affecting the world, not much in everyday life remains the same. Economies from the largest to the smallest have been rocked. Government lockdowns have been undertaken, the likes of which have never been experienced in the modern world. With the virus originating in Wuhan, China, several questions remain:

How has the virus spread so rapidly across the globe?

How long are incubation rates?

What is the most accurate testing method?

How much time is needed to develop a safe and effective vaccine?

And, of course, how and when to reopen our communities?

In time, many of these questions will be researched and answered, but along the way some trends have become noteworthy. For instance, the SARS-CoV-2 virus has affected some groups worse than others and this necessitates further investigation as to why. I was made aware of research being done by Dr. Larry Tilley, DVM, a world-renowned expert in veterinary medicine research, Dr. William Baumgartl, MD, MSME, director of Stem Cell Therapies at Nevada Spine Center, and Jeffrey Gold, a computer science and data analyst. Their paper hypothesizes the reason for higher rates of morbidity and mortality in older versus younger patients suffering from COVID-19.

They note other trends as well. Women seem to be statistically less likely to die from the disease than men. Pacific Islanders and Asian cultures appear less impacted by the virus and appear to have a higher resistance. They cite, Japan, a country of over 126 million, reported 16,325 cases with less than 800 deaths. Mongolia, a nation of 5 million, has only 42 confirmed cases and zero deaths. Whereas Italy, France, Germany, and Spain have had a much higher incidence in morbidity and mortality.

Their research found a possible link in protection against COVID-19 between individuals that received measles, mumps and rubella (MMR) vaccinations and those who did not. They found that the younger population - those under 50 - were the first group to be vaccinated with one dose of MMR vaccine between 1971-1978. From 1979 forward, there were generally two vaccination doses given. Also, women contemplating pregnancy tended to receive additional MMR boosters. Observation of this relationship was also reported in a University of Cambridge study, which reported a 29 percent commonality between the spike proteins of rubella and the SARS-CoV-2 virus, critical for viral penetration of target cells, suggesting that the MMR vaccine may protect against COVID-19.

There are other observations they cite which suggests a relation between MMR vaccination and a decreased rate of morbidity and mortality. First, the U.S. military requires MMR vaccinations for all service members when entering service. The aircraft carrier U.S.S. Roosevelt had a COVID-19 outbreak on board in February of this year. As of April 24, there were 840 individuals who tested positive and one death out of approximately 4,200 sailors. Of those individuals who tested positive, only seven required hospital care and none are currently in the ICU. The second point is countries around the world that initiated the most stringent MMR vaccination programs versus those that did not have had less morbidity and mortality, following the trend. These observations hint at the possibility of cross-protection generated by the MMR vaccines against COVID-19.

As countries and people around the world await a SARS-CoV-2 vaccine, I believe the scientific community and government experts directing the response to COVID-19 need to analyze these findings. If this research can be verified, it may be possible to initiate a rapid MMR vaccination program for the most vulnerable populations and follow that with an effective and safe coronavirus vaccine once it is available. There are many lives that hang in the balance, and research like this could show us a path to saving numerous individuals across the globe.

Ted S. Yoho, DVM, represents Floridas 3rd District.

Original post:
Potential cross-reactivity between MMR vaccinations and COVID-19 | TheHill - The Hill

Read More...

What is a cytokine storm? And why is its prevention key to treating Covid-19? – Scroll.in

Wednesday, May 27th, 2020

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others, it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognise pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the Covid-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognise the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes Covid-19. This suggests that keeping the right balance of innate response is crucial for the survival of Covid-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection. Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further a process known an vasolidation leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the Covid-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for Covid-19 is, in part, based on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel originally developed by Bruce Beutler which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is $22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in Covid-19.

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University.

This article first appeared on The Conversation.

Read more from the original source:
What is a cytokine storm? And why is its prevention key to treating Covid-19? - Scroll.in

Read More...

Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players – Surfacing Magazine

Wednesday, May 27th, 2020

The global Adipose Derived Stem Cell Therapy Market research report thoroughly explains each and every aspect related to the Adipose Derived Stem Cell Therapy Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of a thorough examination offers in-depth information regarding the global Adipose Derived Stem Cell Therapy Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Adipose Derived Stem Cell Therapy Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/1249

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalAdipose Derived Stem Cell TherapyMarket Includes:BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Regions & Countries Mentioned In The Adipose Derived Stem Cell Therapy Market Report:

Key Highlights of the Table of Contents:

Adipose Derived Stem Cell Therapy Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Adipose Derived Stem Cell Therapy Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Adipose Derived Stem Cell Therapy Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Adipose Derived Stem Cell Therapy Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/1249

Table of Contents

Report Overview:It includes the Adipose Derived Stem Cell Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Adipose Derived Stem Cell Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Adipose Derived Stem Cell Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Adipose Derived Stem Cell Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/1249

Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.SPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Read the original:
Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players - Surfacing Magazine

Read More...

Stem Cell Therapy Market COVID 19 Impacted In-Depth Analysis including key players Mesoblast , Regeneus , US Stem Cell , Anterogen , Asterias…

Wednesday, May 27th, 2020

North America, Europe, China, Japan, Rest of the World,May 2020, The Stem Cell TherapyMarket research report includes an in-sight study of the keyGlobal Stem Cell Therapy Marketprominent players along with the company profiles and planning adopted by them. This helps the buyer of the Stem Cell Therapyreport to gain a clear view of the competitive landscape and accordingly plan Stem Cell Therapy market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Stem Cell Therapy specifications, and company profiles. The Stem Cell Therapy study is segmented by Module Type, Test Type, And Region.

The market size section gives the Stem Cell Therapymarket revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Stem Cell Therapyindustry over a defined period.

Download Full PDF Sample Copy of Report:jcmarketresearch.com/report-details/16450/sample

The research covers the current market size of the Global Stem Cell Therapy Marketand its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Global Stem Cell Therapy Market, by applications Osteoarthritis (unspecified) Knee Osteoarthritis Shoulder Osteoarthritis Hip Osteoarthritisin overall market. The in-depth information by segments of Stem Cell Therapymarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Global Stem Cell Therapy Market.

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of Global Stem Cell Therapy Market. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Global Stem Cell Therapy(Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Monotherapy Combination Therapy

The research study is segmented by Application such as Laboratory, Industrial Use, Public Services & Others with historical and projected market share and compounded annual growth rate.Global Stem Cell Therapy(Thousands Units) by Regions (2019-2025)

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Stem Cell Therapyin these regions, from 2012 to 2022 (forecast), covering

Get Exclusive Discount:jcmarketresearch.com/report-details/16450/discount

There are 15 Chapters to display theGlobal Stem Cell Therapy Market.

Chapter 1, to describe Definition, Specifications and Classification of Stem Cell Therapy, Applications of Stem Cell Therapy, Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis ofStem Cell Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis by Mesoblast , Regeneus , U.S. Stem Cell , Anterogen , Asterias Biotherapeutics;

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc.,Stem Cell TherapySegment Market Analysis Monotherapy Combination Therapy ;

Chapter 7 and 8, to analyze theStem Cell TherapySegment Market Analysis (by Application) Major Manufacturers Analysis ofStem Cell Therapy;Mesoblast , Regeneus , U.S. Stem Cell , Anterogen , Asterias Biotherapeutics

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Monotherapy Combination Therapy , Market Trend by Application Osteoarthritis (unspecified) Knee Osteoarthritis Shoulder Osteoarthritis Hip Osteoarthritis;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis ofStem Cell Therapy;

Chapter 12, to describeStem Cell TherapyResearch Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describeStem Cell Therapysales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquiry before Buying The full report @:jcmarketresearch.com/report-details/16450/enquiry

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHJay (Marketing Manager)Phone:+1 (925) 478-7203Email:[emailprotected]

View post:
Stem Cell Therapy Market COVID 19 Impacted In-Depth Analysis including key players Mesoblast , Regeneus , US Stem Cell , Anterogen , Asterias...

Read More...

Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry…

Wednesday, May 27th, 2020

New York City, United States Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Pressure Guidewires MarketPressure Guidewire Market Segmented By Flat Tipped Pressure Guidewires, Flexible Tipped Pressure Guidewires Product with Pressure Wire Technology, Optical Fiber Technology Type for Hospitals, Ambulatory Surgical Centers, Independent Catheterization Labs.For More Information

Compression Therapy Devices MarketThe compression therapy market of North America is projected to escalate from US$ 2,377.8 Mn in 2014 to US$ 1,515.4 Mn, registering a CAGR of 5.4% by 2020-end.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

See the original post:
Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry...

Read More...

Drug factories: GMOs and gene editing are poised to transform medicine. Here’s how. – Genetic Literacy Project

Wednesday, May 27th, 2020

No one likes getting a shot at the doctors office. As kids, we werent used to having a sharp needle prick our skin, let alone by someone doing it on purpose. An estimated 10% of the population is affected by trypanophobia the fear of needles or injections. Luckily, for most, shots are an infrequent occurrence often limited to vaccinations. However, for millions of others, injections are a more frequent fact of life required in dealing with disease. The need for these injections and their associated doctor visits mean the physical discomfort of the treatment is often compounded by a financial burden.

Fortunately, plant biotechnology is poised to drastically improve how we consume medication. Using the modern tools of genetic engineering, researchers are developing plant-based drugs that are cheaper, easier to take and even more effective than their existing counterparts.

Cant more medicines be reformulated for oral delivery?

While many diseases can be treated with orally administered medications, other drugs such as biologics or biopharmaceuticals, medicines derived from living organisms, must be delivered using other strategies. Conventional drugs like aspirin are chemically synthesized and can survive digestion, whereas biologics like hormones, antibodies, enzymes, and other complex organic molecules are vulnerable to degradation by enzymes in our saliva and stomach, as well as environmental conditions like pH and heat. This makes biologics in pill form unlikely to survive the harsh environment of the digestive tract.

Pricey biologics

In addition to the unpleasant nature of biologic injections is their associated costs. Biologics are made by taking the DNA blueprint for the molecule and expressing it in bacterial, yeast, or mammalian cells. Once these cells, typically grown in large vats filled with nutrient media, produce the molecule of interest, it must be isolated and purified. Each step of this process must be exact and carefully maintained as small variations may change the structure and identity of the drug, potentially altering its behavior. This complex manufacturing process in addition to more rigorous FDA regulations mean higher drug prices for consumers. Combined with the price of doctor visits to get these frequent injections or infusions, the annual cost of some biologics can reach hundreds of thousands of dollars.

There are more than 200 FDA-approved biologic drugs. While less than two percent of people in the US rely on biologics, they make up 40 percent of prescription drug spending. Identifying a better way to produce and administer biologics has the potential to ease the physical and financial burden associated with these drugs. For this reason, researchers are turning to the original inspiration for medications: plants.

Turning plants into pharmaceutical factories

Evidence for plant use in medicine dates back all the way to the Palaeolithic Age. But instead of trying to find new plants that produce medically relevant compounds, researchers are turning to genetic engineering to express the same biologics currently grown in bacterial, yeast, or mammalian cells.

Producing biologics in plants has a number of advantages. Plants are potentially less costly to grow, requiring inexpensive fertilizers instead of specialized cell culture growth media. Plants can also be grown in fields or greenhouses without requiring sterile environments, meaning that scaling up production would just require more growing area as opposed to additional expensive bioreactors. An added benefit is that plants do not serve as hosts for human pathogens, reducing the likelihood of harm from contaminants that bacterial or mammalian cells may house.

Once the drug-producing plants are grown, the medically relevant proteins may be extracted and purified. But plants allow for this platform to be taken one step further: by turning the biologic- expressing plants into a freeze-dried (lyophilized) powder and placing it into a capsule, the drugs can be delivered orally. Plant cell walls contain cellulose which cannot be digested by enzymes in the stomach but can be broken down by the commensal bacteria living in our intestines. Plant-encapsulated drugs are then released in the blood-rich absorptive environment of the small intestine, where they become bioavailable and distributed to target tissues. By producing these drugs in a lyophilized form, manufacturers can cut out the expensive purification process and the need for cold transport and storage.

Current research efforts

Theres been some reported success using this method, including a March 2020 paper from a team at the University of Pennsylvania describing a lettuce expressing a novel human insulin-like growth factor-1 (IGF-1). IGF-1 helps promote skeletal muscle and bone development. For this reason, IGF-1 injections have been used in the treatment of several muscle disorders and have the potential for therapeutic benefit in healing bone fractures.

To study if plant-grown IGF-1 might be an effective replacement for traditional IGF injections, the team modified human IGF-1 to allow for uptake through the gut. They found that their modified version not only stimulated proliferation of several cell types better than current commercial IGF-1, but also that the plant-encapsulated drug could be administered orally to mice and would effectively be delivered to blood serum. The team also found that this administration of the drug significantly increased bone density in diabetic mice as compared to a control group.

In addition to medication production, companies are also looking to utilize some of the benefits of plant-based production for vaccines. Medicago, a Canada-based company seeking approval for their plant-produced flu vaccine, has announced that using this same technology, they have produced a candidate vaccine for COVID-19 in twenty days. By growing the protein for the vaccine in plants, as opposed to using eggs to propagate the virus, Medicago has been able to cut the cost and time required to produce a new vaccine. The vaccine is now awaiting clinical testing and FDA approval.

Similar to the work on orally administered IGF-1, theres also a lot of interest in making edible vaccines. In the future, you may no longer need to go to a clinic to get a seasonal flu vaccine, but instead eat a salad made with vaccine-containing lettuce or tomatoes. This could potentially reduce patient discomfort and increase vaccine compliance, minimizing everybodys risk of contracting infectious diseases. Edible vaccines would also help expand access to immunization in parts of the world were delivering vaccines may be difficult.

Plant-produced pharmaceuticals have the potential to improve the quality of life for millions of people by reducing the physical and financial burden of relying on biologics to stay healthy. There may even come a day when getting a shot at the doctors office is a thing of the past replaced by a quick trip to the grocery store.

Tautvydas Shuipys is a PhD candidate in the Genetics and Genomics Graduate Program at the University of Florida. Follow him on Twitter @tshuipys

Go here to see the original:
Drug factories: GMOs and gene editing are poised to transform medicine. Here's how. - Genetic Literacy Project

Read More...

Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Market : Industry Analysis and… – Azizsalon News

Wednesday, May 27th, 2020

Global Clustered Regularly Interspaced Short Palindromic Repeats Market was valued US$ 711.24 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX% during a forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/21900/

The key driving factors of the global clustered regularly interspaced short palindromic repeats market are increasing demand for drug discovery, a risk of congenital anomalies, late pregnancies leading to birth disorders, increasing size of the geriatric population, and investment in path-breaking research technology. Lack of awareness and probable misappropriated use of the CRISPR gene editing tool are the major factors limiting the CRISPR market growth.

The global clustered regularly interspaced short palindromic repeats market is segmented into the products, application, end-uses, and region. In terms of products, the global clustered regularly interspaced short palindromic repeats market is classified into design tools, plasmids, vectors, library, control kits, proteins, genomic RNA, and other products.

Based on the application, the global clustered regularly interspaced short palindromic repeats market is divided into genome editing & genetic engineering, GRNA database & gene library, CRISPR plasmid, human stem cells, and cell line engineering. By application, genome editing & genetic engineering is used for modifying an organisms genome, where deletions, insertions or replacements are carried out in the DNA of the living organism by making use of molecular machinery and engineered nucleases.

In terms of end-uses, global clustered regularly interspaced short palindromic repeats market is segmented into industrial biotech biological research, agricultural research, and therapeutics and drug discovery. changing lifestyles, late pregnancies leading to birth disorders, increasing demand for drug discovery, synthetic genes leading the way, investment in path-breaking research technology and aging genetic disorders are drive the growth of biological research segment.

Based on regions, the global clustered regularly interspaced short palindromic repeats market is divided into five main regions are America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Geographically, Asia-Pacific market is anticipated to be the fastest-growing region in the global CRISPR market due to the large population of Japan and China is suffering from diabetes and other peripheral diseases, and the prevalence of these diseases growing at a very reckless rate.

Key players operating in global clustered regularly interspaced short palindromic repeats market are Addgene, CRISPR Therapeutics, Editas Medicine, Egenesis, Inc., GE Healthcare, GenScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., and Lonza Group.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/21900/

The objective of the report is to present comprehensive analysis of Global Clustered Regularly Interspaced Short Palindromic Repeats Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Clustered Regularly Interspaced Short Palindromic Repeats Market dynamics, structure by analyzing the market segments, and project the Global Clustered Regularly Interspaced Short Palindromic Repeats Market size. Clear representation of competitive analysis of key players by Global Clustered Regularly Interspaced Short Palindromic Repeats Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Clustered Regularly Interspaced Short Palindromic Repeats Market make the report investors guide.The Scope of the Global Clustered Regularly Interspaced Short Palindromic Repeats Market:

Global clustered regularly interspaced short palindromic repeats market, by products:

Design tools Plasmids Vectors Library Control kits Proteins Genomic RNA Other productsGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By Application:

Genome editing & genetic engineering GRNA database & gene library CRISPR plasmid Human stem cells Cell line engineeringGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By End-Uses:

Industrial biotech Biological research Agricultural research Therapeutics and drug discoveryGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By Region:

North America Europe Middle East & Africa Asia Pacific Latin AmericaKey Players Operating In Global Clustered Regularly Interspaced Short Palindromic Repeats Market:

Addgene CRISPR Therapeutics Editas Medicine Egenesis, Inc. GE Healthcare GenScript Biotech Corporation Horizon Discovery Group PLC Integrated DNA Technologies, Inc. Intellia Therapeutics, Inc. Lonza Group

MAJOR TOC OF THE REPORT

Chapter One: Clustered Regularly Interspaced Short Palindromic Repeat Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Competition, by Players

Chapter Four: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Size by Regions

Chapter Five: North America Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Six: Europe Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Seven: Asia-Pacific Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Eight: South America Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Clustered Regularly Interspaced Short Palindromic Repeat by Countries

Chapter Ten: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Segment by Type

Chapter Eleven: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Segment by Application

Chapter Twelve: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Clustered Regularly Interspaced Short Palindromic Repeat Market Report at: https://www.maximizemarketresearch.com/market-report/global-clustered-regularly-interspaced-short-palindromic-repeats-market/21900/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Connect With us at LinkedIn LinkedIn

Connect with us at Facebook Facebook

Contact With Us at Twitter Twitter

Originally posted here:
Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Market : Industry Analysis and... - Azizsalon News

Read More...

Global Food Enzymes Market (2020 to 2025) – Recent Innovations in the Market – GlobeNewswire

Wednesday, May 27th, 2020

Dublin, May 26, 2020 (GLOBE NEWSWIRE) -- The "Food Enzymes Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The food enzymes market is bifurcated by type into variants such as carbohydrates, lipases, and proteases. Innovation has enabled the players to exploit several end-user industries such as bakery, dairy, beverages, meat products, and confectionery, consequently triggering the opportunities in the food enzymes market to be progressing at a compound annual growth rate (CAGR) of 5.90% during the forecast period 2019-2025.

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the food enzyme market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis.

The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various types of application industry in global food enzyme market, and their specific advantages.

The booming trend of fast-food in North America has augmented the trade of cheese, indirectly impacting the market of protease food enzyme. According to the Centers for Disease Control and Prevention, in 2016, one out of three Americans (36%) consumed a meal at fast-food eateries on any given day. Some of the leading fast-food chains across the U.S are McDonald's, KFC, Pizza Hut, Domino's Pizza and Burger Kings. Application of cheese in these F&B giants can be indicated by the fact that Leprino Foods, a leading market player, often rated as America's all-time monopolist, manages to converge an annual revenue of $3 billion by supplying mozzarella cheese to Pizza Hut, Domino's, and Papa John's

Similarly, McDonald's for their buns claims to apply enzymes such as amylases. And KFC, the world's most popular chicken restaurant chain is now operating in 135 countries with more than 22,000 restaurants globally. Hence, the trend of processed food supplemented by retail outlets in North America is projecting the food enzyme market towards exponential growth.

Food Enzymes Market Trends and Growth Drivers:

Some of the key players operating in the global food enzyme market are Royal DSM N.V, EI DuPont DE Nemours & Co., Novozymes A/S, Chr Hansen A/S, Biocatalyst limited, AB enzymes GMBH, Kerry group PLCAum Enzymes, Amano Enzyme Inc., and Enmex SA DE CV.

Key Questions Addressed in the Food Enzyme Market Report

A few focus points of this Research are given below:

Key Topics Covered:

1. Food Enzymes Market - Overview1.1. Definitions and Scope

2. Food Enzymes Market - Executive summary2.1. Market Revenue, Market Size and Key Trends by Company2.2. Key Trends by type of Application2.3. Key Trends segmented by Geography

3. Food Enzymes Market 3.1. Comparative analysis3.1.1. Product Benchmarking - Top 10 companies3.1.2. Top 5 Financials Analysis3.1.3. Market Value split by Top 10 companies3.1.4. Patent Analysis - Top 10 companies3.1.5. Pricing Analysis

4. Food Enzymes Market Forces4.1. Drivers4.2. Constraints4.3. Challenges4.4. Porters five force model4.4.1. Bargaining power of suppliers4.4.2. Bargaining powers of customers4.4.3. Threat of new entrants4.4.4. Rivalry among existing players4.4.5. Threat of substitutes

5. Food Enzymes Market -Strategic analysis5.1. Value chain analysis5.2. Opportunities analysis5.3. Product life cycle5.4. Suppliers and distributors Market Share

6. Food Enzymes Market - By Type (Market Size -$Million / $Billion)6.1. Market Size and Market Share Analysis 6.2. Application Revenue and Trend Research6.3. Product Segment Analysis6.3.1. Introduction6.3.2. Amylases6.3.3. Catalases6.3.4. Lactases6.3.5. Proteases6.3.6. Lipases6.3.7. Rennet6.3.8. Cellulase6.3.9. Others (Actinidin, Bromelain, Ficin, Lypoxygenase, Invertase, Raffinase & Others)

7. Food Enzymes Market - By Source (Market Size -$Million / $Billion)7.1. Introduction 7.2. Plant-Based Enzymes7.3. Animal-Based Enzymes7.4. Microorganism-Based Enzymes7.4.1. Bacterial7.4.2. Fungal7.4.3. Yeast

8. Food Enzymes Market - By Application (Market Size -$Million / $Billion)8.1. Introduction 8.1.1. Bakery8.1.1.1. Bread8.1.1.2. Cakes8.1.1.3. Crackers & Cookies8.1.2. Dairy 8.1.3. Beverages8.1.4. Meat Products8.1.5. Confectionery8.1.6. Fruits & Vegetables Processing8.1.7. Oil & Fats8.1.8. Starch Processing8.1.9. Inulin & Others

9. Food Enzymes - By Geography (Market Size -$Million / $Billion)9.1. Food Enzymes Market - North America Segment Research9.2. North America Market Research (Million / $Billion)9.2.1. Segment type Size and Market Size Analysis 9.2.2. Revenue and Trends9.2.3. Application Revenue and Trends by type of Application9.2.4. Company Revenue and Product Analysis9.2.5. North America Product type and Application Market Size9.2.5.1. U.S.9.2.5.2. Canada 9.2.5.3. Mexico 9.2.5.4. Rest of North America9.3. Food Enzymes - South America Segment Research9.4. South America Market Research (Market Size -$Million / $Billion)9.4.1. Segment type Size and Market Size Analysis 9.4.2. Revenue and Trends9.4.3. Application Revenue and Trends by type of Application9.4.4. Company Revenue and Product Analysis9.4.5. South America Product type and Application Market Size9.4.5.1. Brazil 9.4.5.2. Venezuela9.4.5.3. Argentina9.4.5.4. Ecuador9.4.5.5. Peru9.4.5.6. Colombia 9.4.5.7. Costa Rica9.4.5.8. Rest of South America9.5. Food Enzymes - Europe Segment Research9.6. Europe Market Research (Market Size -$Million / $Billion)9.6.1. Segment type Size and Market Size Analysis 9.6.2. Revenue and Trends9.6.3. Application Revenue and Trends by type of Application9.6.4. Company Revenue and Product Analysis9.6.5. Europe Segment Product type and Application Market Size9.6.5.1. U.K 9.6.5.2. Germany 9.6.5.3. Italy 9.6.5.4. France9.6.5.5. Netherlands9.6.5.6. Belgium9.6.5.7. Spain9.6.5.8. Denmark9.6.5.9. Rest of Europe9.7. Food Enzymes - APAC Segment Research9.8. APAC Market Research (Market Size -$Million / $Billion)9.8.1. Segment type Size and Market Size Analysis 9.8.2. Revenue and Trends9.8.3. Application Revenue and Trends by type of Application9.8.4. Company Revenue and Product Analysis9.8.5. APAC Segment - Product type and Application Market Size9.8.5.1. China 9.8.5.2. Australia9.8.5.3. Japan 9.8.5.4. South Korea9.8.5.5. India9.8.5.6. Taiwan9.8.5.7. Malaysia

10. Food Enzymes Market - Entropy10.1. New product launches10.2. M&A's, collaborations, JVs and partnerships

11. Food Enzymes Market Company Analysis11.1. Market Share, Company Revenue, Products, M&A, Developments11.2. Royal DSM N.V11.3. EI DuPont DE Nemours & Co11.4. Novozymes A/S11.5. Biocatalyst limited11.6. AB enzymes GMBH11.7. Kerry group PLC

12. Food Enzymes Market -Appendix12.1. Abbreviations12.2. Sources

For more information about this report visit https://www.researchandmarkets.com/r/ujmz9s

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:
Global Food Enzymes Market (2020 to 2025) - Recent Innovations in the Market - GlobeNewswire

Read More...

Global Genome Editing/Genome Engineering Market 2020 by Company, Regions, Type and Application, Forecast to 2026 – 3rd Watch News

Wednesday, May 27th, 2020

The dedicated research report titled Global Genome Editing/Genome Engineering Market 2020 by Company, Regions, Type and Application, Forecast to 2026 envelopes all-in information of the market and vital understanding on the global market at a holistic global perspective, rendering statistical analysis, and perspective of integral growth enablers prompting favorable growth across regions. The report is the result of an in-depth analysis of the latest developments which focus on the growth opportunities, the basic criteria, challenges dominant in the global Genome Editing/Genome Engineering market, and their consequential effects on the target market. The report analyzes various products or service implementations in various end-user industries and analyses technology used to create and operate these products/ services in the global market.

Key Vendor/Manufacturers In The Market:

The study analysis examines each market player according to its market share, production footprint, and growth rate during 2020 to 2026 time-frame. Then, the market study determines the recent launches, agreements, R&D projects, and business strategies of the market players. Great insights such as Genome Editing/Genome Engineering market revenue and market share of the global market are also covered. Additionally company basic information, manufacturing base, and competitors list is being provided for each listed manufacturers: Thermo Fisher Scientific, Merck KGaA, Horizon Discovery, Genscript USA, Sangamo Biosciences, Integrated DNA Technologies, Origene Technologies, Transposagen Biopharmaceuticals, Lonza Group, New England Biolabs,

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/47794

All key regions and countries are assessed here on the basis of company, type of product, and application covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Segment by type, the market is segmented into: CRISPR, TALEN, ZFN, Antisense, Other Technology

Segment by application, the market is segmented into: Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Other,

Moreover, the report highlights external as well as internal factors that are expected to affect the global Genome Editing/Genome Engineering industry positively or negatively. PORTER, PESTEL analysis with the potential impact of economic factors by region on the global market is given in the report. Then, the demand-side factors are assessed and shifts in demand patterns across different sub-segments and regions are examined. It also delivers comprehensive information on raw materials suppliers, equipment suppliers, manufacturing cost, capacity, production, profit margin, capacity utilization rate, etc.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/47794/global-genome-editinggenome-engineering-market-2020-by-company-regions-type-and-application-forecast-to-2026

The Report Provides The Following Information:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Continued here:
Global Genome Editing/Genome Engineering Market 2020 by Company, Regions, Type and Application, Forecast to 2026 - 3rd Watch News

Read More...

Swine Circovirus Vaccine Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 – 3rd Watch…

Wednesday, May 27th, 2020

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Swine Circovirus Vaccine market. It informs readers about key trends and opportunities in the global Swine Circovirus Vaccine market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Swine Circovirus Vaccine market.

Key companies operating in the global Swine Circovirus Vaccine market include Chopper Biology, ChengDu Tecbond, Ringpu Biology, Qilu Animal, DHN, CAVAC, Komipharm, Jinyu Bio-Technology, Zoetis, Merial, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1777181/covid-19-impact-on-swine-circovirus-vaccine-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Swine Circovirus Vaccine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Swine Circovirus Vaccine Market Segment By Type:

, Genetic Engineering Vaccine, Killed Vaccines

Global Swine Circovirus Vaccine Market Segment By Application:

,Piglets,Adults Pigs

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Swine Circovirus Vaccine market.

Key companies operating in the global Swine Circovirus Vaccine market include Chopper Biology, ChengDu Tecbond, Ringpu Biology, Qilu Animal, DHN, CAVAC, Komipharm, Jinyu Bio-Technology, Zoetis, Merial, etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1777181/covid-19-impact-on-swine-circovirus-vaccine-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Swine Circovirus Vaccine Industry1.7 COVID-19 Impact: Swine Circovirus Vaccine Market Trends 2 Global Swine Circovirus Vaccine Quarterly Market Size Analysis2.1 Swine Circovirus Vaccine Business Impact Assessment COVID-192.1.1 Global Swine Circovirus Vaccine Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Swine Circovirus Vaccine Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Swine Circovirus Vaccine Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global Swine Circovirus Vaccine Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Swine Circovirus Vaccine Factory Price by Manufacturers3.3 Location of Key Manufacturers Swine Circovirus Vaccine Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Swine Circovirus Vaccine Market3.5 Key Manufacturers Swine Circovirus Vaccine Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Swine Circovirus Vaccine Segments, By Type4.1 Introduction1.4.1 Genetic Engineering Vaccine1.4.2 Killed Vaccines4.2 By Type, Global Swine Circovirus Vaccine Market Size, 2019-20214.2.1 By Type, Global Swine Circovirus Vaccine Market Size by Type, 2020-20214.2.2 By Type, Global Swine Circovirus Vaccine Price, 2020-2021 5 Impact of Covid-19 on Swine Circovirus Vaccine Segments, By Application5.1 Overview5.5.1 Piglets5.5.2 Adults Pigs5.2 By Application, Global Swine Circovirus Vaccine Market Size, 2019-20215.2.1 By Application, Global Swine Circovirus Vaccine Market Size by Application, 2019-20215.2.2 By Application, Global Swine Circovirus Vaccine Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Chopper Biology7.1.1 Chopper Biology Business Overview7.1.2 Chopper Biology Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.1.3 Chopper Biology Swine Circovirus Vaccine Product Introduction7.1.4 Chopper Biology Response to COVID-19 and Related Developments7.2 ChengDu Tecbond7.2.1 ChengDu Tecbond Business Overview7.2.2 ChengDu Tecbond Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.2.3 ChengDu Tecbond Swine Circovirus Vaccine Product Introduction7.2.4 ChengDu Tecbond Response to COVID-19 and Related Developments7.3 Ringpu Biology7.3.1 Ringpu Biology Business Overview7.3.2 Ringpu Biology Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.3.3 Ringpu Biology Swine Circovirus Vaccine Product Introduction7.3.4 Ringpu Biology Response to COVID-19 and Related Developments7.4 Qilu Animal7.4.1 Qilu Animal Business Overview7.4.2 Qilu Animal Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.4.3 Qilu Animal Swine Circovirus Vaccine Product Introduction7.4.4 Qilu Animal Response to COVID-19 and Related Developments7.5 DHN7.5.1 DHN Business Overview7.5.2 DHN Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.5.3 DHN Swine Circovirus Vaccine Product Introduction7.5.4 DHN Response to COVID-19 and Related Developments7.6 CAVAC7.6.1 CAVAC Business Overview7.6.2 CAVAC Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.6.3 CAVAC Swine Circovirus Vaccine Product Introduction7.6.4 CAVAC Response to COVID-19 and Related Developments7.7 Komipharm7.7.1 Komipharm Business Overview7.7.2 Komipharm Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.7.3 Komipharm Swine Circovirus Vaccine Product Introduction7.7.4 Komipharm Response to COVID-19 and Related Developments7.8 Jinyu Bio-Technology7.8.1 Jinyu Bio-Technology Business Overview7.8.2 Jinyu Bio-Technology Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.8.3 Jinyu Bio-Technology Swine Circovirus Vaccine Product Introduction7.8.4 Jinyu Bio-Technology Response to COVID-19 and Related Developments7.9 Zoetis7.9.1 Zoetis Business Overview7.9.2 Zoetis Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.9.3 Zoetis Swine Circovirus Vaccine Product Introduction7.9.4 Zoetis Response to COVID-19 and Related Developments7.10 Merial7.10.1 Merial Business Overview7.10.2 Merial Swine Circovirus Vaccine Quarterly Production and Revenue, 20207.10.3 Merial Swine Circovirus Vaccine Product Introduction7.10.4 Merial Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 Swine Circovirus Vaccine Supply Chain Analysis8.1.1 Swine Circovirus Vaccine Supply Chain Analysis8.1.2 Covid-19 Impact on Swine Circovirus Vaccine Supply Chain8.2 Distribution Channels Analysis8.2.1 Swine Circovirus Vaccine Distribution Channels8.2.2 Covid-19 Impact on Swine Circovirus Vaccine Distribution Channels8.2.3 Swine Circovirus Vaccine Distributors8.3 Swine Circovirus Vaccine Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Swine Circovirus Vaccine Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - 3rd Watch...

Read More...

Amid the COVID-19 crisis and the looming economic recession, the D-Amino Acids market worldwide will grow by a projected US$49.4 Million, during the…

Wednesday, May 27th, 2020

New York, May 27, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global D-Amino Acids Industry" - https://www.reportlinker.com/p05621748/?utm_source=GNW 7 Million by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Pharmaceutical market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 2.3% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$1.2 Million to the regions size over the next 7 to 8 years. In addition, over US$1.2 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Pharmaceutical segment will reach a market size of US$8.6 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the D-Amino Acids market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the worlds second largest economy will grow at 6.9% over the next couple of years and add approximately US$15.9 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing D-Amino Acids market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, GoPro, Inc.; Infineon Technologies AG; Intel Corporation; Kula 3D Ltd.; LG Electronics; Matter and Form Inc.; Microsoft Corp.; pmdtechnologies GmbH; Samsung Electronics Co., Ltd.; Sharp Corporation; Texas Instruments Inc.; Toshiba Corporation

Read the full report: https://www.reportlinker.com/p05621748/?utm_source=GNW

D-AMINO ACIDS MCP-7MARKET ANALYSIS, TRENDS, AND FORECASTS, JUNE 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW D-Amino Acids: A Compound with Promising Applications Recent Market Activity Developing Regions - At the Forefront of Growth in D-Amino Acids Market Pharmaceuticals: D-Amino Acids Hold Edge as Essential Raw Material Rising Prominence of Artificial Amino Acids Augurs Well for Market Growth Global Competitor Market Shares D-Amino Acids Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS Adisseo France S.A.S (France) Ajinomoto Co., Inc. (Japan) AnaSpec, Inc. (USA) Evonik Industries AG (Germany) IRIS Biotech GmbH (Germany) LifeSpan Biosciences, Inc. (USA) Merck KGaA (Germany) Sekisui Medical Co., Ltd. (Japan) Shanghai Hanhong Chemical Co., Ltd. (China) Sichuan Tongsheng Amino acid Co., Ltd. (China) Sumitomo Chemical Company Limited (Japan) TCI America, Inc. (USA) Tocris Bioscience (UK) Zhangjiagang Huachang Pharmaceutical Co., Ltd. (China) 3. MARKET TRENDS & DRIVERS Aging World Population - A Major Growth Influencing Factor for D-Amino Acids Growing Importance of D-Amino Acids in Pharmaceutical Industry Peptide-based Drugs: A Promising Area for D-Amino Acids Growing Interest in Peptide Research Drives D-Amino Acids Market Pharmaceutical Intermediates Market Challenged by Drug Development A Review of Select Research Studies on D-Amino Acids Research Finds Support for Potential Use of D-Amino Acids as Biomarkers for CKD D-Amino Acids and Small Molecule Inhibitors: Potential Role in Eliminating Infections Researchers Develop New Approach to Switch Chirality in Amino Acids Generating Stable D-Amino Acid Analogs Using Mirror Image Version of PDB Ajinomoto Develops Ajiphase and Corynex Amino Acid Synthesis Technologies Harvard University's Scientists Discover New Biofilm Disrupting Bacteria Study Reveals that D-Amino Acids Amass in EMCs Research Studies Suggest that Replacement of One L-Amino Acid with Analogous D-enantiomer Results in High Therapeutic Index ARCA: A Breakthrough Chiral Converting Agent for Amino Acids Commercial Development of ARCA Genetic Engineering and Advances in Research Enable DAAO Use in Multiple Arenas DL-Methionine: An Eco-Friendly Option for Animal Nutrition 4. GLOBAL MARKET PERSPECTIVE Table 1: D-Amino Acids Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 2: D-Amino Acids Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019 Table 3: D-Amino Acids Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 Table 4: Pharmaceutical (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2020-2027 Table 5: Pharmaceutical (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2012-2019 Table 6: Pharmaceutical (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2012 VS 2020 VS 2027 Table 7: Industrial (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2020-2027 Table 8: Industrial (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2012-2019 Table 9: Industrial (End-Use) Market Share Shift across Key Geographies: 2012 VS 2020 VS 2027 Table 10: Other End-Uses (End-Use) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 11: Other End-Uses (End-Use) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2012-2019 Table 12: Other End-Uses (End-Use) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US D-Amino Acids Market Share (in %) by Company: 2020 & 2025 Market Analytics Table 13: United States D-Amino Acids Latent Demand Forecasts in US$ Thousand by End-Use: 2020 to 2027 Table 14: D-Amino Acids Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2012-2019 Table 15: D-Amino Acids Market Share Breakdown in the United States by End-Use: 2012 VS 2020 VS 2027 CANADA Table 16: Canadian D-Amino Acids Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 17: D-Amino Acids Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 18: Canadian D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 JAPAN Table 19: Japanese Demand Estimates and Forecasts for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 20: Japanese D-Amino Acids Market in US$ Thousand by End-Use: 2012-2019 Table 21: D-Amino Acids Market Share Shift in Japan by End-Use: 2012 VS 2020 VS 2027 CHINA Table 22: Chinese Demand for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 23: D-Amino Acids Market Review in China in US$ Thousand by End-Use: 2012-2019 Table 24: Chinese D-Amino Acids Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 EUROPE Market Facts & Figures European D-Amino Acids Market: Competitor Market Share Scenario (in %) for 2020 & 2025 Market Analytics Table 25: European D-Amino Acids Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027 Table 26: D-Amino Acids Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019 Table 27: European D-Amino Acids Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 Table 28: European D-Amino Acids Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 29: D-Amino Acids Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 30: European D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 FRANCE Table 31: D-Amino Acids Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2020-2027 Table 32: French D-Amino Acids Historic Market Review in US$ Thousand by End-Use: 2012-2019 Table 33: French D-Amino Acids Market Share Analysis: A 17-Year Perspective by End-Use for 2012, 2020, and 2027 GERMANY Table 34: D-Amino Acids Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2020-2027 Table 35: German D-Amino Acids Market in Retrospect in US$ Thousand by End-Use: 2012-2019 Table 36: D-Amino Acids Market Share Distribution in Germany by End-Use: 2012 VS 2020 VS 2027 ITALY Table 37: Italian Demand for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 38: D-Amino Acids Market Review in Italy in US$ Thousand by End-Use: 2012-2019 Table 39: Italian D-Amino Acids Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 UNITED KINGDOM Table 40: United Kingdom Demand Estimates and Forecasts for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 41: United Kingdom D-Amino Acids Market in US$ Thousand by End-Use: 2012-2019 Table 42: D-Amino Acids Market Share Shift in the United Kingdom by End-Use: 2012 VS 2020 VS 2027 SPAIN Table 43: Spanish D-Amino Acids Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 44: D-Amino Acids Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 45: Spanish D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 RUSSIA Table 46: Russian D-Amino Acids Latent Demand Forecasts in US$ Thousand by End-Use: 2020 to 2027 Table 47: D-Amino Acids Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2012-2019 Table 48: D-Amino Acids Market Share Breakdown in Russia by End-Use: 2012 VS 2020 VS 2027 REST OF EUROPE Table 49: Rest of Europe D-Amino Acids Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 50: D-Amino Acids Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 51: Rest of Europe D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 ASIA-PACIFIC Table 52: Asia-Pacific D-Amino Acids Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 53: D-Amino Acids Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2012-2019 Table 54: Asia-Pacific D-Amino Acids Market Share Analysis by Region/Country: 2012 VS 2020 VS 2027 Table 55: D-Amino Acids Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2020-2027 Table 56: Asia-Pacific D-Amino Acids Historic Market Review in US$ Thousand by End-Use: 2012-2019 Table 57: Asia-Pacific D-Amino Acids Market Share Analysis: A 17-Year Perspective by End-Use for 2012, 2020, and 2027 AUSTRALIA Table 58: D-Amino Acids Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2020-2027 Table 59: Australian D-Amino Acids Market in Retrospect in US$ Thousand by End-Use: 2012-2019 Table 60: D-Amino Acids Market Share Distribution in Australia by End-Use: 2012 VS 2020 VS 2027 INDIA Table 61: Indian D-Amino Acids Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 62: D-Amino Acids Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 63: Indian D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 SOUTH KOREA Table 64: D-Amino Acids Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2020-2027 Table 65: South Korean D-Amino Acids Historic Market Analysis in US$ Thousand by End-Use: 2012-2019 Table 66: D-Amino Acids Market Share Distribution in South Korea by End-Use: 2012 VS 2020 VS 2027 REST OF ASIA-PACIFIC Table 67: Rest of Asia-Pacific Demand Estimates and Forecasts for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 68: Rest of Asia-Pacific D-Amino Acids Market in US$ Thousand by End-Use: 2012-2019 Table 69: D-Amino Acids Market Share Shift in Rest of Asia-Pacific by End-Use: 2012 VS 2020 VS 2027 LATIN AMERICA Table 70: Latin American D-Amino Acids Market Trends by Region/Country in US$ Thousand: 2020-2027 Table 71: D-Amino Acids Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2012-2019 Table 72: Latin American D-Amino Acids Market Percentage Breakdown of Sales by Region/Country: 2012, 2020, and 2027 Table 73: Latin American Demand for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 74: D-Amino Acids Market Review in Latin America in US$ Thousand by End-Use: 2012-2019 Table 75: Latin American D-Amino Acids Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 ARGENTINA Table 76: Argentinean D-Amino Acids Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 77: D-Amino Acids Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 78: Argentinean D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 BRAZIL Table 79: D-Amino Acids Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2020-2027 Table 80: Brazilian D-Amino Acids Historic Market Review in US$ Thousand by End-Use: 2012-2019 Table 81: Brazilian D-Amino Acids Market Share Analysis: A 17-Year Perspective by End-Use for 2012, 2020, and 2027 MEXICO Table 82: D-Amino Acids Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2020-2027 Table 83: Mexican D-Amino Acids Market in Retrospect in US$ Thousand by End-Use: 2012-2019 Table 84: D-Amino Acids Market Share Distribution in Mexico by End-Use: 2012 VS 2020 VS 2027 REST OF LATIN AMERICA Table 85: Rest of Latin America D-Amino Acids Latent Demand Forecasts in US$ Thousand by End-Use: 2020 to 2027 Table 86: D-Amino Acids Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2012-2019 Table 87: D-Amino Acids Market Share Breakdown in Rest of Latin America by End-Use: 2012 VS 2020 VS 2027 MIDDLE EAST Table 88: The Middle East D-Amino Acids Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027 Table 89: D-Amino Acids Market in the Middle East by Region/Country in US$ Thousand: 2012-2019 Table 90: The Middle East D-Amino Acids Market Share Breakdown by Region/Country: 2012, 2020, and 2027 Table 91: The Middle East D-Amino Acids Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2020 to 2027 Table 92: D-Amino Acids Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2012-2019 Table 93: The Middle East D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 IRAN Table 94: Iranian Demand Estimates and Forecasts for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 95: Iranian D-Amino Acids Market in US$ Thousand by End-Use: 2012-2019 Table 96: D-Amino Acids Market Share Shift in Iran by End-Use: 2012 VS 2020 VS 2027 ISRAEL Table 97: Israeli D-Amino Acids Addressable Market Opportunity in US$ Thousand by End-Use: 2020-2027 Table 98: D-Amino Acids Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2012-2019 Table 99: Israeli D-Amino Acids Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 SAUDI ARABIA Table 100: Saudi Arabian Demand for D-Amino Acids in US$ Thousand by End-Use: 2020 to 2027 Table 101: D-Amino Acids Market Review in Saudi Arabia in US$ Thousand by End-Use: 2012-2019 Table 102: Saudi Arabian D-Amino Acids Market Share Breakdown by End-Use: 2012 VS 2020 VS 2027 UNITED ARAB EMIRATES Table 103: D-Amino Acids Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2020-2027 Table 104: United Arab Emirates D-Amino Acids Historic Market Analysis in US$ Thousand by End-Use: 2012-2019 Table 105: D-Amino Acids Market Share Distribution in United Arab Emirates by End-Use: 2012 VS 2020 VS 2027 REST OF MIDDLE EAST Table 106: D-Amino Acids Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2020-2027 Table 107: Rest of Middle East D-Amino Acids Market in Retrospect in US$ Thousand by End-Use: 2012-2019 Table 108: D-Amino Acids Market Share Distribution in Rest of Middle East by End-Use: 2012 VS 2020 VS 2027 AFRICA Table 109: African D-Amino Acids Latent Demand Forecasts in US$ Thousand by End-Use: 2020 to 2027 Table 110: D-Amino Acids Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2012-2019 Table 111: D-Amino Acids Market Share Breakdown in Africa by End-Use: 2012 VS 2020 VS 2027 IV. COMPETITION

Total Companies Profiled: 31 Read the full report: https://www.reportlinker.com/p05621748/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the rest here:
Amid the COVID-19 crisis and the looming economic recession, the D-Amino Acids market worldwide will grow by a projected US$49.4 Million, during the...

Read More...

Lessons From Operation "Denver," the KGB’s Massive AIDS Disinformation Campaign – The MIT Press Reader

Wednesday, May 27th, 2020

Historian Douglas Selvage sheds light on a conspiracy theory that reverberates to this day.

By: Mark Kramer

In September 1985, the Soviet State Security Committee (KGB) informed other Warsaw Pact foreign intelligence agencies that it had launched a new, major disinformation campaign. We are carrying out a complex of [active] measures in connection with the appearance in recent years of a new dangerous disease in the USA known as AIDS (Acquired Immunodeficiency Syndrome). The KGB explained that the goal of the measures is to create a favorable opinion for us abroad namely, that this disease is the result of secret experiments by the USAs secret services and the Pentagon with new types of biological weapons that have spun out of control. Most likely, the KGB had initiated the disinformation campaign as early as 1983, but the September 1985 document obtained by Christopher Nehring from the former Bulgarian State Security archive is the earliest conclusive evidence that has turned up so far. (The former KGB foreign intelligence archive has never been accessible to researchers.)

Among the East European intelligence services that assisted the KGB in this effort was the East German Ministry for State Security (Stasi), which used the codename Denver when referring to the campaign. The KGB and Stasi relied on forged documents and inaccurate testimony from purported experts to suggest that HIV, the virus that causes AIDS, had originated not from infected animals in Africa but from biological warfare research carried out by U.S. military scientists at Fort Detrick in Maryland. Operation Denver proved remarkably effective, writes historian Douglas Selvage in an article featured in a recent issue of the Journal of Cold War Studies; indeed, even more effective than the KGB and Stasi had originally expected. Before long, immense numbers of people around the world (including in the United States) came to believe, falsely, that the U.S. government was responsible for AIDS.

The conspiracy theories circulating in 2020 are more diffuse and less coherent than the disinformation propagated by the KGB and the Stasi in the 1980s, but the two periods bear distinct similarities.

Selvages article appeared a few months before Covid-19 burst into public consciousness. The Covid-19 pandemic has provoked a wide range of lurid conspiracy theories in countries whose governments are hostile to the United States, notably Russia, China, Iran, and Venezuela. The conspiracy theories circulating in 2020 are more diffuse and less coherent than the disinformation propagated by the KGB and the Stasi in the 1980s, but the two periods bear distinct similarities. In both cases, authoritarian regimes have exploited widespread public fear and confusion to generate suspicions about U.S. motives, to stoke hostility toward the United States, and to discredit the U.S. governments sincerity in combatting the global pandemic.

In our exchange featured below, Selvage sheds light on the origins and main purpose of operation Denver and considers the lessons we may learn in responding to Russian and Chinese disinformation in 2020.

Mark Kramer: The Soviet KGB was the agency that originated the AIDS disinformation campaign, but the KGB enlisted the East German Stasi early on to help out. To what extent did other Soviet-bloc intelligence agencies also participate? Did the Stasi play the lead role after the Soviet KGB?

Douglas Selvage: Based on statements by KGB and Stasi officers to their Bulgarian counterparts in 1986-9, the Stasis foreign intelligence branch (Hauptverwaltung Aufklrung, HVA) played a central role in the disinformation campaign alongside the KGB. Bulgarian and especially Czechoslovak foreign intelligence also assisted, but mainly in terms of spreading leaflets around U.S. military bases and encouraging stories in the local press in NATO countries. These claimed (falsely) that U.S. service members suffered a high infection rate with HIV and were spreading AIDS locally around U.S. military bases. The Cuban government also played a role in spreading AIDS disinformation about the U.S. in Latin America, but the details remain unclear.

M.K.: Why did the Stasi give the codename Denver to the disinformation campaign?

D.S.: We actually do not know why the Stasi chose this particular codename because the HVA destroyed around 90 percent of its records in 1989-90, including the files for Operation Denver. One can only speculate. It is possible that a Stasi officer heard the term Fort Detrick and thought Denver instead of Detrick that is, a geographical term more familiar to most Germans. At the time, a popular program on West German television, also viewed in East Germany, was Denver-Clan, the German name for the popular U.S. television series Dynasty. But this is all just speculation. As early as 1987, the Stasi officers responsible for the AIDS disinformation campaign began using the terms Denver and Detrick interchangeably in talks with their Bulgarian counterparts. The use of Denver had apparently created some confusion.

One term that never came up in talks between the Stasi and their Bulgarian counterparts, let alone in talks between the KGB and the Bulgarians, was Operation Infektion. Despite this fact, practically the entire internet continues to use this incorrect codename in discussing the KGBs AIDS disinformation campaign. The New York Times even decided to use it as the title for its series of popular videos about Soviet and Russian disinformation.

M.K.: What was the main purpose of Operation Denver? What were the main types of disinformation activities?

D.S.: The KGB informed its Bulgarian colleagues in September 1985 that it had initiated a campaign of active measures that is, covert propaganda regarding HIV/AIDS. The goal of these measures, the KGB wrote, is to create a favorable opinion for us abroad that this disease is the result of secret experiments with a new type of biological weapon by the secret services of the USA and the Pentagon that spun out of control. Around a year later, the Stasi wrote to the Bulgarians about Operation Denver, its contribution to the KGBs AIDS disinformation campaign. Through the operation, the Stasi sought to expose the dangers to mankind arising from the research, production, and use of biological weapons, to strengthen anti-American sentiments in the world, and to spark domestic political controversies in the USA. To this end, the Stasi promised to provide their Bulgarian comrades with a scientific study and other materials that prove that AIDS originated in the USA, not in Africa, and that AIDS is a product of the USAs bioweapons research.

Through the operation, the Stasi sought to expose the dangers to mankind arising from the research, production, and use of biological weapons, to strengthen anti-American sentiments in the world, and to spark domestic political controversies in the USA.

The scientific study to which the Stasi referred was clearly AIDS: Its Nature and Origin by the retired Soviet-East German biologist Jakob Segal and his wife, Lilli, a scientist and author in her own right. The Stasi claimed to have played a role in photocopying and distributing the study in a brochure entitled, AIDS: USA home-made evil, NOT out of AFRICA at a summit meeting of the Non-Aligned Movement in Harare, Zimbabwe in August-September 1986. This was a gathering of world leaders, mainly from the less-developed countries, that had proclaimed their neutrality in the superpower rivalry during the Cold War. Journalists, especially from Africa, reported on the Segals findings. The Segals were claiming just like the KGB, but on the basis of a more scientific analysis that HIV had leaked out of a U.S. military biological-weapons research lab at Fort Detrick, Maryland. The U.S. military, the Segals claimed, had used the very new technology of genetic engineering to construct HIV from two other dangerous viruses, including one that infected sheep.

Many leaders, journalists, and intellectuals in Africa welcomed the Segals thesis of a U.S. origin of HIV as an alternative to the hypothesis of many leading U.S. and Western scientists at the time. The latter were arguing correctly, as it later turned out that HIV had originated in Africa, where it had spread from non-human primates to human beings. Many Africans interpreted this hypothesis, especially given the scant evidence at the time, as an attempt to blame Africa and Africans for HIV/AIDS. In the weeks following the Harare summit, the Segals Fort-Detrick-thesis of AIDS origins spread throughout the press in Africa, India, and the world.

The Stasi apparently helped behind the scenes in bringing the Segals together with certain foreign journalists who were known quantities to its disinformation division. The official Soviet press agency Novosti also helped to spread the thesis abroad, alongside the KGB. The KGB happily noted that foreign journalists, without any prompting on its part, were also picking up on the claims and reporting them. For example, officials from the Reagan Administration were perturbed that Dan Rather reported the Soviets accusations about AIDS and Fort Detrick on the CBS Evening News in 1987 without requesting a U.S. government response.

The Stasi apparently helped behind the scenes in bringing the Segals together with certain foreign journalists who were known quantities to its disinformation division.

The Stasi also claimed to have covertly co-financed a documentary film shown three times on public-financed West German television in 1989 and subsequently in an English version on British Channel Four in 1990. The film featured an interview with the Segals, who expounded upon their thesis; conversations with journalists and African scientists, who denounced the hypothesis of a natural origin of AIDS in Africa as racist; and U.S. and Western critics of the ostensibly defensive U.S. biological-weapons research program. (No mention was made of the Soviet Unions much larger, offensive biological-weapons research program, but little was publicly known about it at the time.)

The two co-creators of the West German film strenuously deny that the Stasi covertly financed the film or was involved with it in any other way. They also deny that they ever had any contacts to the Stasi. Whatever the case may be, officers from the Stasis disinformation division, ostensibly convinced that the film contributed to their goals for Operation Denver, encouraged Bulgarian and apparently also Czechoslovak foreign intelligence to covertly support the sale and distribution of the films German and English versions in non-communist countries.

The German film or perhaps a bootleg version can still be viewed on YouTube today.

M.K.: When you began writing about the Soviet-East German AIDS disinformation campaign, did you ever imagine that you might live through a global pandemic that would give rise to lurid conspiracy theories in Russia, China, and Iran claiming that the deadly pathogen was manufactured in U.S. biological defense laboratories?

D.S.: Strangely, in retrospect, I did not imagine living through another global pandemic in my lifetime, despite the warnings of the Obama Administration and the example of the HIV/AIDS pandemic. Many more of us should have known better.

Still, as a historian, I am not surprised that conspiracy theories would arise in response to the Covid-19 pandemic. Since the Middle Ages, if not long before, people have responded to epidemics and pandemics by trying to find a responsible party or parties, often in the form of a scapegoat. For example, some Christians in Europe blamed the Jews for the bubonic plague and responded with violence and murder.

Since the Middle Ages, if not long before, people have responded to epidemics and pandemics by trying to find a responsible party or parties, often in the form of a scapegoat.

Often, victims of repression and real conspiracies also respond with suspicion to pandemics and other disasters, and to explain the seemingly inexplicable, they craft conspiracy theories. For example, the KGB was not the first to accuse the U.S. government of constructing the AIDS virus. Already in 1983, some members of the gay community in the U.S. had accused the federal government of constructing the virus in order to kill off gay Americans. This came at least partly in response to their frustration with decades of discrimination, the accelerating death toll from HIV/AIDS, and the lagging, at times callous, response of the Reagan Administration to the pandemic. As it became clear that African-Americans were also suffering disproportionately from the disease, some African-Americans came to believe in and spread similar conspiracy theories. Such accusations seemed plausible to many, given the history of racism in the United States, including in the medical field. One particularly reprehensible episode was the Tuskegee syphilis study, in which the U.S. Public Health Service had observed the long-term effects of syphilis on infected African-American sharecroppers and their offspring for four decades, from 1932 to 1972, without providing them with effective medical treatment, even after penicillin had proven effective against the disease.

Of course, political extremists, in and out of power, often develop or exploit conspiracy theories to their own ends. In my article for the Journal of Cold War Studies, I demonstrate how the perennial right-wing U.S. Presidential candidate Lyndon LaRouche and his organization promoted a variant of the AIDS-from-Fort-Detrick thesis. They promoted the claim that a Soviet fifth column had infiltrated the National Institutes of Health through the World Health Organization and then genetically engineered the AIDS virus at the National Cancer Institutes facilities at Fort Detrick. Although LaRouches organization counter-attacked the KGB disinformation with its own version of the Fort Detrick thesis, and the KGB and Moscow attacked LaRouche, both apparently borrowed elements from each others conspiracy theory in constructing their own.

A cycle of misinformation and disinformation arose in which the KGB cited U.S. conspiracy theories, and U.S. conspiracy theorists, in turn, began to cite texts associated with KGB disinformation.

In the case of the AIDS disinformation campaign, the KGB simply picked up on existing conspiracy theories in the U.S, added a new element that conformed to its disinformation goals (i.e., the exact location of HIVs construction, Fort Detrick), and spread the resulting conspiracy theory internationally to its own ends. A cycle of misinformation and disinformation arose in which the KGB cited U.S. conspiracy theories, and U.S. conspiracy theorists, in turn, began to cite texts associated with KGB disinformation.

One can see a similar dynamic today between Russian disinformation and U.S. conspiracy theorists if one closely views Sputnik News and RT (formerly Russia Today) on Twitter and Facebook. Already during the Ebola epidemic in West Africa in 2013-16, these Russian propaganda outlets spread reports that the virus had been created by the U.S. in collaboration with Great Britain and South Africa in order to kill off Africans. That is, different virus, similar disinformation. So, it did not surprise me that certain propagandists in Russia spread similar rumors about the origin of Covid-19. Since I knew less about Chinese disinformation efforts, it surprised me that Beijing apparently decided to revamp the old, Soviet disinformation and to apply it to the new virus.

M.K.: What are the lessons we can learn from Operation Denver in responding to the Russian and Chinese disinformation now?

D.S.: During the Cold War, the Reagan Administration had an Active Measures Working Group that exposed and publicized examples of Soviet disinformation. It was particularly active in combatting the Soviet blocs AIDS disinformation. Over the long term, the ongoing exposure of Soviet disinformation efforts sparked a backlash internationally, helped discredit Soviet propaganda agencies and created effective pressure on the Soviet Union to curtail or at least to limit its activities. A similar, intensive effort by the U.S. and other democracies could also prove effective today. NATO allies such as Estonia have adopted such measures, but the U.S. is lagging behind.

From my perspective, it would be even more important, especially for the long term, to train students as early as elementary school to differentiate between facts and opinions and to identify not only propaganda techniques, but also fallacies in logic. There were some initiatives in this regard during the Cold War in the United States. I dont know if they still continue today. Students and others would also benefit from training in internet literacy: What sources can one trust, and how can one fact-check various claims, especially before reposting them?

Students and others would also benefit from training in internet literacy: What sources can one trust, and how can one fact-check various claims, especially before reposting them?

There is one thing that democratic governments should definitely avoid in responding to disinformation namely, spreading conspiracy theories and disinformation themselves. Of course, during the Cold War, the U.S. and other democracies did this, if not to the same extent as the Soviet Union and its allies.

Today, it absolutely does not help, for example, when the Trump Administration and other U.S. politicians openly promote their own conspiracy theories about Covid-19, including basically unsubstantiated claims that the virus escaped from a Chinese laboratory in Wuhan. This leads to fruitless public discussion along the lines of: Who was responsible for constructing the virus China or the U.S.? Such apparently baseless accusations also make the public, especially in third countries, less willing to listen to other, substantiated criticisms of Chinas response to the pandemic, including its initial suppression of warnings from doctors in Wuhan. The Chinese government has succeeded to some extent in lumping together accusations about the Wuhan laboratory with all other criticisms of its role and response to the pandemic as mere China-bashing.

The promotion of conspiracy theories regarding a viruss origins can also undermine public health efforts to mitigate its spread and save lives. Studies show that individuals who believe in conspiracy theories regarding the origins of HIV/AIDS are less likely to follow medical advice regarding safe sex, to test themselves for potential infection, or to take effective medications to contain the disease. Such behaviors, of course, can lead to death. Apparently, believers in HIV/AIDS conspiracy theories reason as follows: If scientists and medical doctors cannot be trusted to tell the truth or have been duped themselves about a viruss origins, why should one trust their medical or public health advice? Not surprisingly, there are also individuals who have turned a profit by selling publications with their own versions of the HIV/AIDS conspiracy theory alongside their own unproven, alternative therapies for the disease. In the case of HIV/AIDS, such quack therapies have included aspirin, alfa-interferon, the ultraviolet irradiation of blood, vitamin cocktails, traditional Chinese or African herbs, and colloidal silver. With regard to Covid-19 today, we see the spread of similar conspiratorial beliefs, an associated rejection of public health measures, and a similar propagation of unproven and potentially dangerous alternative therapies.

With regard to Covid-19 today, we see the spread of similar conspiratorial beliefs, an associated rejection of public health measures, and a similar propagation of unproven and potentially dangerous alternative therapies.

The example of the response to the HIV/AIDS pandemic by the democratically-elected government of South Africa under President Thabo Mbeki (1999-2008) should serve as a warning to us today as we grapple with Covid-19. He and his health minister came to believe in various conspiracy theories regarding HIV/AIDS from the internet, including the Fort Detrick thesis. They thus rejected the mainstream medical science on HIV/AIDS and came to promote various unproven alternative therapies some mentioned above for treating the disease. It has been estimated that the ensuing delay in the introduction of effective antiretroviral treatment for HIV/AIDS in South Africa contributed to up to 300,000 additional deaths from the disease.

Mark Kramer is director of Cold War Studies at Harvard Universitys Davis Center for Russian and Eurasian Studies, and the editor of the Journal of Cold War Studies.

Douglas Selvage is a Research Associate (wissenschaftlicher Mitarbeiter) at the Institute for History of the Humboldt University in Berlin.

See the original post here:
Lessons From Operation "Denver," the KGB's Massive AIDS Disinformation Campaign - The MIT Press Reader

Read More...

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 – Jewish Life News

Wednesday, May 27th, 2020

In this report, the COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026. COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry.

Based on our recent survey, we have several different scenarios about the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in terms of revenue.

Players, stakeholders, and other participants in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

The following players are covered in this report:

Orange County Hair Restoration Center

Hair Sciences Center of Colorado

Anderson Center for Hair

Evolution Hair Loss Institute

Savola Aesthetic Dermatology Center

Virginia Surgical Center

Hair Transplant Institute of Miami

Colorado Surgical Center & Hair Institute

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Type

Platelet Rich Plasma Injections

Stem Cell Therapy

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application

Dermatology Clinics

Hospitals

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 911 Central Avenue #268Albany New York 12206Email: [emailprotected]Phone: 1-518-730-1569Web: https://www.crystalmarketreport.com

Read the original:
COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 - Jewish Life News

Read More...

Global Stem Cell Therapy Market 2020 Top Manufactures, Growth Opportunities and Investment Feasibility 2026 – Surfacing Magazine

Wednesday, May 27th, 2020

Released by MarketsandResearch.biz, Global Stem Cell Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2026 profoundly explores an overarching research study which talks about the current market scenario. The report explains the overall global Stem Cell Therapy market journey in the previous five years along with the prophecy made by the experts in the industry. The report attributes product innovation, and technological advancements boosting market development in the near future. A comprehensive study of key market dynamics and current trends, along with relevant market sectors and sub-sectors is offered. The report incorporates important factors such as market opportunities, risk, benefit, opportunity, loss, and profit.

Market Overview:

Data associated with the market on the products, strategies and market share of leading companies of this market are mentioned. Detailed understandings into ongoing industry trends, trend prediction, and growth drivers are offered in the report. Additionally, potential market risks, obstacles, threats, and uncertainties are also determined in the report. Market segments examined in the report include major types, applications, regions, and end-users. This research study features the data about the global Stem Cell Therapy market share held by every region with potential growth prospects on the basis of the regional analysis. The research document serves accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/41722

Competitive rivalry scenario for the global Stem Cell Therapy market: Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix),

The study broadly exemplifies, the regional hierarchy of this market, while categorizing the same into: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Autologous, Allogeneic

On the basis of application, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others,

Drivers & Challenges:

The market report delivers information about the driving factors affecting the revenue scale of this global Stem Cell Therapy industry as well as their influence on the commercialization graph of this business sphere. The research study incorporates the latest trends building up the market in conjunction with the challenges that this business vertical will face over the forecast duration. Additionally, it encompasses the obstacles that this industry will be characterized by, in the forecast timeframe.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/41722/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2026

Report Answers Following Questions:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Here is the original post:
Global Stem Cell Therapy Market 2020 Top Manufactures, Growth Opportunities and Investment Feasibility 2026 - Surfacing Magazine

Read More...

Page 9«..891011..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick